GlassScriptPhysician profile
Asit K Tripathy
NPI 1265609234
$3,763.59
in general payments reported to CMS, 2019-2025
20 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $1,545 · 2022: $437 · 2023: $677 · 2024: $439 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,814.19 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $469.30 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Jazz Pharmaceuticals INC. | $286.20 | 2022-2025 | |
| Neurelis, INC. | $226.77 | 2022-2025 | Valtoco |
| Immedica Pharma US, INC. | $172.84 | 2022-2024 | |
| Lundbeck LLC | $162.74 | 2022 | |
| Alexion Pharmaceuticals, INC. | $160.41 | 2023-2025 | Koselugo |
| Azurity Pharmaceuticals, INC. | $107.57 | 2023 | Horizant |
| Biogen, INC. | $62.16 | 2024-2025 | Spinraza |
| Acadia Pharmaceuticals INC | $53.27 | 2023 | Daybue |
| Sunovion Pharmaceuticals INC. | $45.72 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $42.89 | 2024 | |
| Aquestive Therapeutics, INC. | $26.74 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $26.48 | 2025 | Ajovy |
| Greenwich Biosciences, INC. | $26.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pyros Pharmaceuticals, INC. | $22.53 | 2024 | Vigpoder |
| Baxter Healthcare | $17.54 | 2022 | |
| Biomarin Pharmaceutical INC. | $15.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.29 | 2022 | |
| Mallinckrodt Enterprises LLC | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asit Tripathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.